AOA Dx Builds Oncology Platform Across Three Gynecologic Cancers as Lead Ovarian Cancer Assay Advances Toward Commercialization
Study demonstrates that integrating lipids, metabolites, and proteins reveals coordinated molecular signatures missed by traditional single omic tests.